Related Experiment Videos
[How I treat...fibroproliferative scars].
L Smeets1, F X Grandjean, P Nickers
1Service de Chirurgie Maxillo-faciale et Plastique, Centre des brûlés, Chirurgie de la main, CHU Sart Tilman, Liège.
Revue Medicale De Liege
|February 24, 2006
Summary
Fibroproliferative scars like keloids cause cosmetic and symptomatic issues after skin injury. Current treatments, including surgery with adjuvant therapies, offer the best option, but better understanding of scar pathophysiology is needed for new treatments.
Area of Science:
- Dermatology and Wound Healing
- Biopathology of Scarring
- Extracellular Matrix Remodeling
Context:
- Skin injuries such as burns, trauma, and surgery can lead to fibroproliferative scars.
- Keloids are benign fibroproliferative scars resulting from an imbalance in extracellular matrix synthesis and degradation.
- Existing therapeutic options for keloids often have high recurrence rates and suboptimal outcomes.
Purpose:
- To review current therapeutic modalities for fibroproliferative scars, particularly keloids.
- To highlight the limitations and complications associated with existing treatments.
- To emphasize the need for a deeper understanding of scar pathophysiology to develop novel and more effective therapies.
Summary:
- Fibroproliferative scars, including keloids, arise from dysregulated extracellular matrix metabolism post-skin injury.
- Current treatments, primarily surgery combined with adjuvant therapies like steroids, radiotherapy, or silicone, represent the most effective approach.
- Despite advancements, challenges such as lesion recurrence and increasing size persist, underscoring the need for improved therapeutic strategies.
Impact:
- Improved patient outcomes through more effective management of problematic scarring.
- Potential for new therapeutic targets based on a comprehensive understanding of scar formation.
- Reduced psychological and symptomatic burden associated with significant scarring.